Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.
You may also be interested in...
Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.